# The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer

> **NCT05634590** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 68 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Fruquintinib
- **DRUG:** FOLFIRI
- **DRUG:** mFOLFOX6

## Key facts

- **NCT ID:** NCT05634590
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2022-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05634590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05634590, "The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05634590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*